Synthesis and Discovery of Arylpiperidinylquinazolines

New Inhibitors of the Vesicular Monoamine Transporter

Brian A. Provencher, Amy J. Eshleman, Robert A. Johnson, Xiao Shi, Olga Kryatova, Jared Nelson, Jianhua Tian, Mario Gonzalez, Peter C. Meltzer, Aaron Janowsky

Research output: Contribution to journalArticle

Abstract

Methamphetamine, a human vesicular monoamine transporter 2 (VMAT2) substrate, releases dopamine, serotonin, and norepinephrine from vesicles into the cytosol of presynaptic neurons and induces reverse transport by the monoamine transporters to increase extracellular neurotransmitters. Currently available radioligands for VMAT2 have considerable liabilities: The binding of [3H]dihydrotetrabenazine ([3H]DHTB) to a site on VMAT2 is not dependent on ATP, and [3H]reserpine binds almost irreversibly to VMAT2. Herein we demonstrate that several arylpiperidinylquinazolines (APQs) are potent inhibitors of [3H]reserpine binding at recombinant human VMAT2 expressed in HEK-293 cells. These compounds are biodiastereoselective and bioenantioselective. The lead radiolabeled APQ is unique because it binds reversibly to VMAT2 but does not bind the [3H]DHTB binding site. Furthermore, experimentation shows that several novel APQ ligands have high potency for inhibition of uptake by both HEK-VMAT2 cells and mouse striatal vesicles and may be useful tools for characterizing drug-induced effects on human VMAT2 expression and function.

Original languageEnglish (US)
Pages (from-to)9121-9131
Number of pages11
JournalJournal of Medicinal Chemistry
Volume61
Issue number20
DOIs
StatePublished - Oct 25 2018

Fingerprint

Vesicular Monoamine Transport Proteins
Reserpine
Corpus Striatum
Methamphetamine
HEK293 Cells
Cytosol
Neurotransmitter Agents
Dopamine
Serotonin
Norepinephrine
Adenosine Triphosphate
Binding Sites
Ligands
Neurons

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Synthesis and Discovery of Arylpiperidinylquinazolines : New Inhibitors of the Vesicular Monoamine Transporter. / Provencher, Brian A.; Eshleman, Amy J.; Johnson, Robert A.; Shi, Xiao; Kryatova, Olga; Nelson, Jared; Tian, Jianhua; Gonzalez, Mario; Meltzer, Peter C.; Janowsky, Aaron.

In: Journal of Medicinal Chemistry, Vol. 61, No. 20, 25.10.2018, p. 9121-9131.

Research output: Contribution to journalArticle

Provencher, BA, Eshleman, AJ, Johnson, RA, Shi, X, Kryatova, O, Nelson, J, Tian, J, Gonzalez, M, Meltzer, PC & Janowsky, A 2018, 'Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter', Journal of Medicinal Chemistry, vol. 61, no. 20, pp. 9121-9131. https://doi.org/10.1021/acs.jmedchem.8b00542
Provencher, Brian A. ; Eshleman, Amy J. ; Johnson, Robert A. ; Shi, Xiao ; Kryatova, Olga ; Nelson, Jared ; Tian, Jianhua ; Gonzalez, Mario ; Meltzer, Peter C. ; Janowsky, Aaron. / Synthesis and Discovery of Arylpiperidinylquinazolines : New Inhibitors of the Vesicular Monoamine Transporter. In: Journal of Medicinal Chemistry. 2018 ; Vol. 61, No. 20. pp. 9121-9131.
@article{f297cb26ff7b4329aad18fe9d477da77,
title = "Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter",
abstract = "Methamphetamine, a human vesicular monoamine transporter 2 (VMAT2) substrate, releases dopamine, serotonin, and norepinephrine from vesicles into the cytosol of presynaptic neurons and induces reverse transport by the monoamine transporters to increase extracellular neurotransmitters. Currently available radioligands for VMAT2 have considerable liabilities: The binding of [3H]dihydrotetrabenazine ([3H]DHTB) to a site on VMAT2 is not dependent on ATP, and [3H]reserpine binds almost irreversibly to VMAT2. Herein we demonstrate that several arylpiperidinylquinazolines (APQs) are potent inhibitors of [3H]reserpine binding at recombinant human VMAT2 expressed in HEK-293 cells. These compounds are biodiastereoselective and bioenantioselective. The lead radiolabeled APQ is unique because it binds reversibly to VMAT2 but does not bind the [3H]DHTB binding site. Furthermore, experimentation shows that several novel APQ ligands have high potency for inhibition of uptake by both HEK-VMAT2 cells and mouse striatal vesicles and may be useful tools for characterizing drug-induced effects on human VMAT2 expression and function.",
author = "Provencher, {Brian A.} and Eshleman, {Amy J.} and Johnson, {Robert A.} and Xiao Shi and Olga Kryatova and Jared Nelson and Jianhua Tian and Mario Gonzalez and Meltzer, {Peter C.} and Aaron Janowsky",
year = "2018",
month = "10",
day = "25",
doi = "10.1021/acs.jmedchem.8b00542",
language = "English (US)",
volume = "61",
pages = "9121--9131",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "20",

}

TY - JOUR

T1 - Synthesis and Discovery of Arylpiperidinylquinazolines

T2 - New Inhibitors of the Vesicular Monoamine Transporter

AU - Provencher, Brian A.

AU - Eshleman, Amy J.

AU - Johnson, Robert A.

AU - Shi, Xiao

AU - Kryatova, Olga

AU - Nelson, Jared

AU - Tian, Jianhua

AU - Gonzalez, Mario

AU - Meltzer, Peter C.

AU - Janowsky, Aaron

PY - 2018/10/25

Y1 - 2018/10/25

N2 - Methamphetamine, a human vesicular monoamine transporter 2 (VMAT2) substrate, releases dopamine, serotonin, and norepinephrine from vesicles into the cytosol of presynaptic neurons and induces reverse transport by the monoamine transporters to increase extracellular neurotransmitters. Currently available radioligands for VMAT2 have considerable liabilities: The binding of [3H]dihydrotetrabenazine ([3H]DHTB) to a site on VMAT2 is not dependent on ATP, and [3H]reserpine binds almost irreversibly to VMAT2. Herein we demonstrate that several arylpiperidinylquinazolines (APQs) are potent inhibitors of [3H]reserpine binding at recombinant human VMAT2 expressed in HEK-293 cells. These compounds are biodiastereoselective and bioenantioselective. The lead radiolabeled APQ is unique because it binds reversibly to VMAT2 but does not bind the [3H]DHTB binding site. Furthermore, experimentation shows that several novel APQ ligands have high potency for inhibition of uptake by both HEK-VMAT2 cells and mouse striatal vesicles and may be useful tools for characterizing drug-induced effects on human VMAT2 expression and function.

AB - Methamphetamine, a human vesicular monoamine transporter 2 (VMAT2) substrate, releases dopamine, serotonin, and norepinephrine from vesicles into the cytosol of presynaptic neurons and induces reverse transport by the monoamine transporters to increase extracellular neurotransmitters. Currently available radioligands for VMAT2 have considerable liabilities: The binding of [3H]dihydrotetrabenazine ([3H]DHTB) to a site on VMAT2 is not dependent on ATP, and [3H]reserpine binds almost irreversibly to VMAT2. Herein we demonstrate that several arylpiperidinylquinazolines (APQs) are potent inhibitors of [3H]reserpine binding at recombinant human VMAT2 expressed in HEK-293 cells. These compounds are biodiastereoselective and bioenantioselective. The lead radiolabeled APQ is unique because it binds reversibly to VMAT2 but does not bind the [3H]DHTB binding site. Furthermore, experimentation shows that several novel APQ ligands have high potency for inhibition of uptake by both HEK-VMAT2 cells and mouse striatal vesicles and may be useful tools for characterizing drug-induced effects on human VMAT2 expression and function.

UR - http://www.scopus.com/inward/record.url?scp=85054618156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054618156&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.8b00542

DO - 10.1021/acs.jmedchem.8b00542

M3 - Article

VL - 61

SP - 9121

EP - 9131

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 20

ER -